OTTAWA, Sept. 29, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to
complement today's earlier announcement by GlaxoSmithKline (GSK) Inc.
of a joint investment with the Canadian Institutes of Health Research
(CIHR) and the Université de Sherbrooke for the creation of a new Research Chair in Quebec on the causes of
Type 2 Diabetes.
"This strategic partnership between GSK, CIHR and the Université de Sherbrooke for the creation of a research and education Chair about Type 2
Diabetes is a clear example of the innovative scientific collaborations
being developed in this country that will benefit all Canadians.
"The newly created Chair's activities will be supported by a $1 million
endowment and a matching grant of $375,000 over a five-year period. The
work undertaken will yield a better understanding of Type 2 Diabetes, a
chronic illness currently affecting seven to 10 per cent of the
Canadian population. The research will ultimately give rise to new
clinical management models for the prevention and early treatment of
"According to Diabetes Québec about nine per cent of the adult
population in Quebec or 650 000 people have the disease of which
200,000 are unaware that they have it. The aging of the population will
definitively increase the already high number of people that have
developed the disease and add to the economic burden associated with
diabetes that is currently in the order of $3 billion per year.
"Clearly, the initiative announced today serves our objective that we
share of enhancing Quebec's reputation as a world class centre of
research and innovation. Our lasting partnership includes not only
government and industry, but also academia, health professionals and
the scientific research community.
"Innovation is the key to the future productivity of our country, our
workplaces, our communities and our citizens. Investments in innovation
are an essential part of creating a sustainable health care system, and
developing health care options for people, whether these options are
aimed at better diagnosing disease, better delivering care to people,
or better managing health care systems or processes.
"Enhancing life sciences innovation in Canada depends upon a number of
important policy choices, including improving patient access to
innovative medicines and vaccines, and ensuring that Canada has a
competitive intellectual property regime to better compete with the
European Union, the United States and other leading nations.
"It is by working together that we can consolidate the position of
Canada as a leader in the provision of health care solutions to people
across the country and throughout the world."
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: